Checkpoint Therapeutics (NASDAQ:CKPT) Posts Earnings Results, Misses Expectations By $0.47 EPS

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) issued its earnings results on Friday. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.47), Zacks reports.

Checkpoint Therapeutics Stock Down 0.1 %

Shares of NASDAQ CKPT traded down $0.01 during midday trading on Tuesday, hitting $4.04. The stock had a trading volume of 42,917 shares, compared to its average volume of 1,120,541. The business's 50 day moving average is $3.33 and its 200-day moving average is $3.28. Checkpoint Therapeutics has a 52 week low of $1.38 and a 52 week high of $4.50. The company has a market cap of $197.04 million, a P/E ratio of -2.19 and a beta of 1.41.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CKPT. D. Boral Capital restated a "buy" rating and issued a $4.80 target price on shares of Checkpoint Therapeutics in a report on Monday. HC Wainwright reaffirmed a "neutral" rating and set a $4.10 target price on shares of Checkpoint Therapeutics in a research note on Tuesday, March 11th. Finally, Lake Street Capital reiterated a "hold" rating and set a $4.10 price target (down previously from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th.

Insider Activity at Checkpoint Therapeutics

In other news, CFO William Garrett Gray sold 74,110 shares of the stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $3.67, for a total value of $271,983.70. Following the completion of the sale, the chief financial officer now directly owns 1,458,644 shares of the company's stock, valued at $5,353,223.48. This represents a 4.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO James F. Oliviero III sold 9,233 shares of the firm's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $3.41, for a total transaction of $31,484.53. Following the sale, the chief executive officer now owns 3,785,350 shares in the company, valued at $12,908,043.50. The trade was a 0.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 93,674 shares of company stock valued at $336,011 over the last 90 days. Corporate insiders own 2.10% of the company's stock.

Remove Ads

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.